KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Sales (2020 - 2025)

Historic Return on Sales for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 31.35%.

  • Recursion Pharmaceuticals' Return on Sales fell 276800.0% to 31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.38%, marking a year-over-year decrease of 105800.0%. This contributed to the annual value of 7.88% for FY2024, which is 5200.0% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Return on Sales of 31.35% as of Q3 2025, which was down 276800.0% from 8.94% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Return on Sales peaked at 3.67% during Q3 2024, and registered a low of 39.35% during Q4 2024.
  • Moreover, its 5-year median value for Return on Sales was 8.83% (2023), whereas its average is 12.65%.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Return on Sales soared by 2938200bps in 2021 and then tumbled by -308200bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Return on Sales (Quarter) stood at 25.65% in 2021, then surged by 83bps to 4.46% in 2022, then tumbled by -91bps to 8.54% in 2023, then tumbled by -361bps to 39.35% in 2024, then grew by 20bps to 31.35% in 2025.
  • Its Return on Sales was 31.35% in Q3 2025, compared to 8.94% in Q2 2025 and 13.73% in Q1 2025.